Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Kymera Therapeutics (KYMR) Other Gross PP&E Adjustments (2019 - 2026)

Kymera Therapeutics has reported Other Gross PP&E Adjustments over the past 8 years, most recently at $20.3 million for Q1 2026.

  • Quarterly Other Gross PP&E Adjustments rose 19.43% to $20.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $20.3 million through Mar 2026, up 19.43% year-over-year, with the annual reading at $20.9 million for FY2025, 27.04% up from the prior year.
  • Other Gross PP&E Adjustments was $20.3 million for Q1 2026 at Kymera Therapeutics, down from $20.9 million in the prior quarter.
  • Over five years, Other Gross PP&E Adjustments peaked at $22.4 million in Q3 2025 and troughed at -$33.7 million in Q1 2023.
  • The 5-year median for Other Gross PP&E Adjustments is $9.3 million (2022), against an average of $6.6 million.
  • Year-over-year, Other Gross PP&E Adjustments plummeted 763.15% in 2023 and then soared 826.25% in 2024.
  • A 5-year view of Other Gross PP&E Adjustments shows it stood at $9.3 million in 2022, then tumbled by 81.01% to $1.8 million in 2023, then soared by 826.25% to $16.4 million in 2024, then rose by 27.04% to $20.9 million in 2025, then dropped by 2.57% to $20.3 million in 2026.
  • Per Business Quant, the three most recent readings for KYMR's Other Gross PP&E Adjustments are $20.3 million (Q1 2026), $20.9 million (Q4 2025), and $22.4 million (Q3 2025).